[Studies for a sensitive radioimmunoassay of beta1-Sp1-glycoprotein (SP1) (author's transl)]. 1980

K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama

In order to measure beta1-SP1-glycoprotein (SP1), on RIA system by the 2-antibody method was established as a measuring method of the low concentration range. SP1 concentrations were measured by this method in the sera of women in early pregnancy, in the amniotic fluids of late pregnancy, in the sera of malignant tumour patients. Furthermore, SP1 concentrations in the sera of women in early pregnancy as well as E2, E3, progesterone and HCG concentrations in the same samples were measured, and correlations between them were examined. 1) The minimum sensitivity of this measuring system was 3ng/ml. The optimum concentration of samples was between 10 approximately 660ng/ml. 2) The correlation between the data obtained by this RIA method and the SRID method was as close as r = 0.9287. 3) SP1 concentrations in the sera of women in early pregnancy were 0.17 +/- 0.12 microgram/ml in the fifth week of pregnancy, showing an almost straight increase during the course of pregnancy, and were 31.62 +/- 3.20 microgram/ml in the 13th week of pregnancy. 4) SP1 concentrations in amniotic fluids were 1.09 approximately 2.20 microgram/ml and were equal to about 1% of SP1 concentrations in the sera of women in late pregnancy. SP1 concentrations in the sera of umbilical cord blood were 0.13 approximately microgram/ml, which were equal to about 0.1% of SP1 concentrations in the sera of women in late pregnancy. 5) SP1 was detected in all four samples of the choriocarcinoma patients' sera, and the concentrations were 25 approximately 2,600ng/ml. Sp1 was detected in 6 of the 15 samples of the cervical carcinoma patients' sera, and the detection rate was 40%. SP1 was detected in 3 of the 6 samples of the leukemia patients' sera and 1 of the 4 samples of the prostatic cancer patients' sera. SP1 detection rates and concentrations appeared to increase in the sera of cervical carcinoma and leukemia patients in accordance with the progress of the diseases. SP1 concentrations in the sera of women in early pregnancy were not correlative to measured E2 and E3 concentrations in the same samples, but there was a significant correlation with progesterone and HCG concentrations. The RIA method for measuring SP1, which we have established, is available for measuring SP1 in the low concentration range. The method is expected to be applied clinically, such as in examinations in early pregnancy, and will be available in fundamental studies such as attempts to measure the SP1 movement in malignant tumour patients, in cooperation with studies of the meaning of SP1 production at pregnancy.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011257 Pregnancy Proteins Proteins produced by organs of the mother or the PLACENTA during PREGNANCY. These proteins may be pregnancy-specific (present only during pregnancy) or pregnancy-associated (present during pregnancy or under other conditions such as hormone therapy or certain malignancies.) Placental Proteins,Proteins, Placental,Proteins, Pregnancy
D011261 Pregnancy Trimester, First The beginning third of a human PREGNANCY, from the first day of the last normal menstrual period (MENSTRUATION) through the completion of 14 weeks (98 days) of gestation. Early Placental Phase,Pregnancy, First Trimester,Trimester, First,Early Placental Phases,First Pregnancy Trimester,First Pregnancy Trimesters,First Trimester,First Trimester Pregnancies,First Trimester Pregnancy,First Trimesters,Phase, Early Placental,Phases, Early Placental,Placental Phase, Early,Placental Phases, Early,Pregnancies, First Trimester,Pregnancy Trimesters, First,Trimesters, First
D011268 Pregnancy-Specific beta 1-Glycoproteins Glycoproteins with the electrophoretic mobility of BETA-GLOBULINS, secreted by the placental TROPHOBLASTS into the maternal bloodstream during PREGNANCY. They can be detected 18 days after OVULATION and reach 200 mg/ml at the end of pregnancy. They are associated with fetal well-being. Pregnancy-Specific beta 1-Glycoprotein,SP1 Pregnancy Protein,Trophoblast-Specific beta 1-Glycoprotein,beta 1-Glycoprotein, Pregnancy-Specific,beta-1 Glycoprotein, Trophoblast-Specific,PAPP-B,PAPP-C,PSBG-1,Pregnancy Specific beta 1 Glycoprotein,Pregnancy Specific beta-1 Glycoprotein,Pregnancy Specific beta1-Glycoprotein.,Pregnancy-Associated Plasma Protein B,Pregnancy-Associated Plasma Protein C,Pregnancy-Associated beta-Plasma Protein,Pregnancy-Specific beta-1 Globulin,Schwangerschaftsprotein 1,Trophoblastic beta 1-Glycoprotein,Trophoblastic beta(1)-Globulin,Trophoblastic beta-Globulin,beta 1-Globulin, Trophoblast-Specific,1-Glycoproteins, Pregnancy-Specific beta,PAPP B,PSBG 1,Pregnancy Associated Plasma Protein B,Pregnancy Associated Plasma Protein C,Pregnancy Protein, SP1,Pregnancy Specific beta 1 Globulin,Pregnancy Specific beta 1 Glycoproteins,Protein, SP1 Pregnancy,Trophoblast Specific beta 1 Glycoprotein,Trophoblast-Specific beta 1-Globulin,Trophoblast-Specific beta-1 Glycoprotein,Trophoblastic beta Globulin,beta 1 Globulin, Trophoblast Specific,beta 1-Glycoproteins, Pregnancy-Specific,beta-1 Globulin, Pregnancy-Specific,beta-Globulin, Trophoblastic
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002583 Uterine Cervical Neoplasms Tumors or cancer of the UTERINE CERVIX. Cancer of Cervix,Cancer of the Cervix,Cancer of the Uterine Cervix,Cervical Cancer,Cervical Neoplasms,Cervix Cancer,Cervix Neoplasms,Neoplasms, Cervical,Neoplasms, Cervix,Uterine Cervical Cancer,Cancer, Cervical,Cancer, Cervix,Cancer, Uterine Cervical,Cervical Cancer, Uterine,Cervical Cancers,Cervical Neoplasm,Cervical Neoplasm, Uterine,Cervix Neoplasm,Neoplasm, Cervix,Neoplasm, Uterine Cervical,Uterine Cervical Cancers,Uterine Cervical Neoplasm
D002822 Choriocarcinoma A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL). Choriocarcinomas
D005260 Female Females
D005312 Fetal Blood Blood of the fetus. Exchange of nutrients and waste between the fetal and maternal blood occurs via the PLACENTA. The cord blood is blood contained in the umbilical vessels (UMBILICAL CORD) at the time of delivery. Cord Blood,Umbilical Cord Blood,Blood, Cord,Blood, Fetal,Blood, Umbilical Cord,Bloods, Cord,Bloods, Fetal,Bloods, Umbilical Cord,Cord Blood, Umbilical,Cord Bloods,Cord Bloods, Umbilical,Fetal Bloods,Umbilical Cord Bloods
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
October 1977, Scandinavian journal of clinical and laboratory investigation,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
August 1977, British journal of obstetrics and gynaecology,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
July 1974, Archiv fur Gynakologie,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
June 1981, Nihon Naibunpi Gakkai zasshi,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
January 1982, Nihon Sanka Fujinka Gakkai zasshi,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
January 1980, Annales d'endocrinologie,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
April 1981, Radioisotopes,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
September 1977, Obstetrical & gynecological survey,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
September 1979, Kaku igaku. The Japanese journal of nuclear medicine,
K Maeda, and Y Nishiyama, and Y Nose, and K Murata, and H Yamaguchi, and M Ito, and S Hayakawa, and H Imaizumi, and Y Sugiyama
October 1974, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
Copied contents to your clipboard!